Dr. Waldman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
132 S 10th St
# 1170
Philadelphia, PA 19107Phone+1 215-955-6086Fax+1 215-955-5681
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1987 - 1990
- Stanford University School of MedicineClass of 1987
Certifications & Licensure
- CA State Medical License 1988 - Present
- PA State Medical License 1991 - 2024
Clinical Trials
- Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer Start of enrollment: 2013 Oct 01
- Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer Start of enrollment: 2019 Oct 30
- GCC Agonist Signal in the Small Intestine Start of enrollment: 2022 Nov 30
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 366 citationsCardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified bio...Jozef Bartunek, Atta Behfar, Dariouch Dolatabadi, Marc Vanderheyden, Miodrag Ostojic
Journal of the American College of Cardiology. 2013-06-11 - 21 citationsCardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes.Jozef Bartunek, Andre Terzic, Beth A. Davison, Atta Behfar, Ricardo Sanz-Ruiz
ESC Heart Failure. 2020-10-23 - 156 citationsCardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial.Jozef Bartunek, Andre Terzic, Beth A. Davison, Gerasimos Filippatos, Slavica Radovanovic
European Heart Journal. 2016-12-18
Press Mentions
- FDA Panel Says Poziotinib’s Benefits Don’t Outweigh Risks in NSCLC With HER2 Exon 20 MutationsSeptember 22nd, 2022
- Climate Science Deniers Turn to Attacking Coronavirus ModelsApril 15th, 2020
- Positive Phase I Results for Colorectal Cancer VaccineMay 3rd, 2019
- Join now to see all
Grant Support
- Gastro Intestinal CancerNational Cancer Institute2010–2011
- Clinical Pharmacology Training ProgramNational Institute Of General Medical Sciences1997–2011
- Occult Lymph Node Metastases And Racial Disparities In Colon Cancer OutcomesNational Cancer Institute2009–2010
- Training Program In Human InvestigationNational Center For Research Resources2005–2009
- Guanylyl Cyclase C In Blood And Colorectal CancerNational Cancer Institute2003–2008
- Short-Term Training Program In Translational Cancer ReseNational Cancer Institute2003–2007
- Guanylyl Cyclase C As A Bi0marker For Colorectal CancerNational Cancer Institute2002–2006
- Training Program In Human InvestigationNational Heart, Lung, And Blood Institute2000–2004
- Core--Developmental TherapeuticsNational Cancer Institute2001–2002
- Short Term Training Program--Translational Cancer ResearNational Cancer Institute1997–2001
- Guanylyl Cyclase C In Blood And Colorectal CancerNational Cancer Institute1999–2000
- Allosteric Inhibition Of Guanylyl Cyclase By NucleotidesNational Heart, Lung, And Blood Institute1998–2000
- Vitamin D3 25-Hydroxylase Characterization &RegulationNational Institute Of General Medical Sciences1999
- Guanylyl Cyclase C As A Biomarker For Colorectal CancerNational Cancer Institute1998–1999
- Molecular Characterization Of E Coli Toxin ReceptorsNational Institute Of Diabetes And Digestive And Kidney Diseases1992
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: